pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo Boston, MA and Perth, Australia – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation today at the Rodman & Renshaw 5th

pSivida new trial to treat AMD (age related macular degeneration) Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that enrolment has begun for a clinical trial to assess the safety and efficacy of Medidur™ FA in conjunction with Lucentis®

Shareholder Meeting - 6 June 2008 Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that the Federal Court of Australia had ordered the convening of a meeting of shareholders to be held on 6 June 2008 to vote on the proposed Scheme of Arrangement

Commentary and Highlights

- Reincorporation Plan Announced
- Medidur Collaboration Agreement Amended
- BrachySil Pancreatic Cancer Phase IIa Results
- Pfizer R&D Quarterly Payments Commence

pSivida proposed reincorporation in the US Boston, MA and Perth, Australia (April 18, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, FSE:PSI) today announced that it proposes to reincorporate in the United States. The reincorporation, which is subject to Australian Federal Court and shareholder

pSivida appoints new Company Secretary Boston, MA and Perth, Australia (April 15, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) is pleased to announce that all the Company’s shares subject to Opes Prime margin lending facilities (approximately 14m ordinary shares) have been sold in an

pSivida appoints new Company Secretary Boston, MA and Perth, Australia (March 27, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that it has appointed Mr Winton Willesee as the Australian Company Secretary. Mr Willesee has broad experience in the company administration of

Open Briefing®. pSivida. Alimera Agreement Amendment pSivida Limited Level 12, BGC Building 28 The Esplanade Perth, Western Australia 6000 Date of lodgement: 19-Mar-2008 Title: Open Briefing®. pSivida. Alimera Agreement Amendment Record of interview: corporatefile.com.au pSivida Ltd.

pSivida generates up to A$82m from licensing amendment with Alimera ATLANTA / BOSTON, March 17, 2008 - Alimera Sciences and pSivida Ltd (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies’ Phase

pSivida to present at Sachs Conference - Boston Boston, MA and Perth, Australia (February 25, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation in Boston today at the Sachs Associates 7th

pSivida receives first R&D payments from Pfizer Boston, MA and Perth, Australia (February 20, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the receipt of US$500k as the first quarterly research and development payment from Pfizer under the terms of the exclusive

Commentary and Highlights

- First R&D funding payments from Pfizer to commence
- BrachySil Pancreatic Cancer Study Results
- pSiNutria Business sold to Intrinsiq

pSivida pancreatic cancer results released Boston, MA and Perth, Australia (January 29, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the results of the Phase IIa clinical trial of BrachySilTM for the treatment of advanced, inoperable pancreatic cancer presented at the

BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium Boston, MA and Perth, Australia (January 23, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, today announced that the final results of the recently

pSivida sells pSiNutria to Intrinsiq(UK) Boston, MA and Perth, Australia (January 21, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, and Intrinsiq Materials Cayman Limited today announced that the assets of pSiNutria Limited, a wholly owned subsidiary of